Extracorporeal Shock Wave Therapy for Achilles and Patellar Tendinopathy: Meta-Analysis and a Systematic Review of the Literature

Anuj Punnoose1, Alan Norrish2, Katie Pak3

1Physiotherapy department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
2Consultant Orthopaedic Surgeon, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
3Lecturer in Medical education, University of East Anglia, Norwich, UK

Corresponding author: Anuj Punnoose, Physiotherapy Lead and Clinical Specialist, Cambridge University Hospitals, NHS Foundation Trust, Cambridge, United Kingdom, Tel: +441223216104; Fax: +441223216989; E-mail: anuj.punnoose@addenbrookes.nhs.uk

Received date: January 04, 2017; Accepted date: January 18, 2017; Published date: January 25, 2017

Copyright: © 2017 Punnoose A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Background: Sports related injuries such as lower limb tendinopathies can result in long-standing impairment of athletic performance. In recent years, treatment interventions like eccentric exercises, Platelet Rich Plasma (PRP) injections and Extracorporeal Shockwave Therapy (ESWT) have gained popularity among Physiotherapists and sports clinicians, but the evidence of their effectiveness is very limited.

Purpose: To investigate the effectiveness of ESWT on Achilles and Patellar tendinopathy.

Methods: A systematic review and meta-analysis was conducted using MEDLINE, EMBASE, AMED, CINAHL, PEDro and Cochrane databases and bibliographic searches from inception until April 2013 to identify randomized control trials comparing ESWT with other treatment methods.

Results: Of 306 titles screened, 9 papers, including 487 patients were included in this review. Meta-analysis showed no significant differences between the intervention and control group on the pooled VISA-A scores (p=0.59, 95% CI-15.02, 26.51) or load-induced pain (p=0.51, 95% CI-3.15, 1.56) for Achilles tendinopathy and no significant differences between the pooled VISA-P scores for patellar tendinopathy (p=0.27, CI-7.86, 27.87).

Conclusions: The meta-analysis did not demonstrate a statistically significant improvement in symptoms or load induced pain for ESWT compared to other treatments or control. Adequately powered, high quality studies with longer follow-ups are required.

Keywords: Shockwave; Tendinopathy; Extracorporeal shockwave therapy

Introduction

Sports related injuries are a constant and disturbing problem for both clinicians and athletes. Among these, overuse injuries may constitute 30-50% of all injuries [1]. Tendon injuries could be either acute or chronic in nature and the choice of treatment would depend on the specific pathology and diagnosis of the condition. Traditionally, emphasis was given on targeting inflammation. However, there has been considerable advancement in the management of tendon disorders in recent years. With the term ‘tendinosis’ and ‘tendinopathy’ replacing ‘tendinitis’ [2] treatment interventions like Eccentric exercises, Platelet Rich Plasma (PRP) and Extracorporeal Shockwave Therapy (ESWT) has gained popularity among sports clinicians in treating tendon related pathologies.

Extracorporeal shockwave therapy (ESWT) is a non-invasive treatment in which a device is used to pass acoustic shockwaves through the skin to the affected area of the body. Similar use of high energy sound waves is seen in lithotripsy for the breakdown of kidney or gall stones [3]. ESWT can be applied in different energy levels over one or more sessions and as high energy ESWT can be painful, is sometimes applied with anesthesia. ESWT is used in the treatment of musculoskeletal conditions such as chronic proximal plantar fasciitis [4] and lateral epicondylitis [5]. However, guidelines for its use in the UK currently recommend use limited to certain conditions or restricted to clinical trials (NICE 2009).

Previous systematic reviews [6] have identified a number of studies on ESWT for lower limb tendinopathies, however these reviews have been limited by the inclusion of relatively few studies with small numbers of patients, potential selection bias (limitedscope/databases/publication bias) and potential reporting bias. Consequently, current evidence to guide clinical practice is inconclusive. This systematic review attempts to address a number of these limitations in the question: ‘Is Extracorporeal Shock Wave Therapy more effective than standard care or other interventions in improving pain and function in the management of Achilles and Patellar tendinopathies?’

Methods

We conducted a systematic review of the literature using standardised methods [7,8] Components of the research question were classified according the PICO acronym [9] P (Population)-adult humans with achilles and patellar tendinopathy; I (Intervention)-ESWT, which can be generated by different methods [10]. C
(Contrast)-compared to "standard care" or another intervention; O (Outcomes) of key interest was reduction in pain and increase in function measured at any time after treatment.

**Literature search**

We searched multiple databases: MEDLINE, CINAHL Plus, EMBASE, AMED, SPORTDiscus and PEDro, from their inception to April 2013. We also searched the Cochrane Trials Register, the ISI Web of Science, International Standard Randomised Control Trial Number (ISRCTN) register and the National Institute of Health (NIH) clinical trials register to identify unpublished studies. Medical Sub Heading (MeSH) terms and keywords including tendon or tendin and intervention-specific words shockwave OR "shock wave" were used (See search strategy Supplementary Data). Reference lists from articles were hand-searched to check for relevant articles not previously identified.

**Eligibility criteria**

We included all randomised control trials (RCT) comparing ESWT to other interventions reported in the English language. We included studies using Focused Shockwave (FSWT) and Radial Shockwave (RSWT) delivery methods, delivered with or without anaesthetic. Studies on both mid-portion and insertional tendinopathies were included. Exclusion criteria included non-human animal studies and studies involving anatomical structures other than tendon.

**Selection of studies**

Titles and abstracts from the search strategy were assessed by AP and in uncertain cases assessed by AN. A third reviewer (KP) acted as referee in cases of disagreement. Full-text versions of papers were obtained to confirm eligibility.

**Data extraction**

Extraction of published data on mean effects and standard deviations was performed by AP and confirmed by AN and KP.

**Outcome measures**

The two main outcomes of interest were function and tendinopathic pain, measured at any time point after the intervention.

We considered outcome in terms similar to the three main domains in the Victorian Institute of Sports Assessment (VISA) score: pain, functional status and the ability to undertake sports [11]. Vissentini et al. considered these domains important in lower limb tendon pathology. 'VISA-P' (Patellar) was converted to a version for Achilles tendon symptoms 'VISA-A' (Achilles) while retaining validity and reliability by Robinson et al. [12].

A reduction in pain, typically recorded on the Visual Analogue Scale (VAS) [13] or Numerical Rating Scale (NRS) [14] whilst loading the tendon was considered a favourable outcome [15].

**Secondary outcome measures**

Functional objective measures like range of motion and strength were analysed where available. Other outcomes included a change in a tendon's structure or diameter (indicators of tendon pathology) measured using ultrasonography [16,17].

**Methodological quality of the included studies**

Included studies were assessed by AP for methodological quality and validity using the Physiotherapy Evidence Database (PEDro) 11-point rating scale [18,19]. The maximum score achievable on a PEDro scale is 10/10 as the first criterion, which measures the external validity of a trial, is not included in the final score. We classified studies as high quality (score of 6 or above) or low-quality (score below 6).

**Analysis**

Summary descriptions of the studies were tabulated. If aggregate data were considered suitable by the authors, we planned to carry out a meta-analysis using Review Manager 5.2. To produce forest plots, calculate summary effects sizes with 95% confidence interval (CI) for effect of ESWT on function and pain.

We identified a priori subgroups of interest as "patellar" and "Achilles" studies and those using Focused Shockwave (FSWT) and Radial Shockwave (RSWT) delivery methods. Our approach would be dependent on the risk of bias and estimated levels of heterogeneity being less than 70%. Results are reported in accordance with the Preferred Reporting Item for Systematic Reviews and Meta-Analyses (PRISMA) guidance [20].

**Results**

**Study selection**

Study selection is shown in Figure 1 with nine studies meeting the inclusion criteria. Searching reference lists of key articles yielded one relevant study [21] not identified in the electronic search.
Study characteristics

Table 1 and 2 describe study characteristics for the Achilles and patellar studies respectively. Generally, mean age in the Achilles studies was greater than the patellar studies, with most studies having more women than men. All studies included patients with symptoms of at least three months duration.

### Table 1: Randomised control trials comparing shock wave to other interventions for achilles tendinopathy.

| Author            | Group                  | Number of Patients and Sex (M/F) | Mean Age (range SD) | Duration of Symptoms | Number of ESWT sessions | Mean Age (range SD) | Number of Intervention sessions | Shockwave Application and Energy level (mJ/mm²) x Impulses | Co-interventions allowed during study period | Length of follow up | Significant differences in advantage of ESWT |
|--------------------|------------------------|----------------------------------|---------------------|----------------------|--------------------------|----------------------|-----------------------------|----------------------------------------------------------|-----------------------------------------------|------------------|-------------------------------------------|
| Peers [21], 2003   | ESWT                   | 20 (12)                          | 45 (14)             | >3 months            | 3                        | 1 week                | Focused 0.2×1000            | Eccentric exercises at week 2                       | 2.6 and 12 weeks                                    | Yes at 12 weeks | 2.6 weeks NR                             |
|                    | Placebo                | 19 (10)                          | 44 (13)             |                      |                          |                      |                             |                                                          |                                               | No at 12 weeks | 1 year NR                                |
| Costa et al. [22], 2005 | ESWT                  | 22 (9)                           | 58.7 (10.8)         | >4 months            | 3                        | 1 month               | Focused 0.2×1500            | None reported                                         | 12 weeks and 1 year                                 | No at 12 weeks | 1 year NR                                |
|                    | Placebo                | 27 (12)                          | 47.7 (15.5)         |                      |                          |                      |                             |                                                          |                                               | No at 12 weeks | 1 year NR                                |
| Rompe et al. [24], 2007 | ESWT                  | 25 (11)                          | 51.2 (10.3)         | >6 months            | 3                        | 1 week                | Radial 0.1×2000            | Crossover was allowed after 16 weeks follow-up        | 16 weeks and 1 year                                 | Yes at 16 weeks | 1 year NR                                |
|                    | EE                     | 25 (9)                           | 48.1 (9.9)          |                      |                          |                      |                             |                                                          |                                               | No at 16 weeks | 1 year NR                                |
| Rasmussen et al. [23], 2008 | ESWT              | 24 (12)                          | 49 (9)              | >3 months            | 4                        | 1 week                | Radial 0.12 to 0.5×1500    | Eccentric training and stretching                     | 8 and 12 weeks                                    | No at 8 and 12 weeks |                                               |
|                    | Placebo                | 24 (8)                           | 46 (13)             |                      |                          |                      |                             |                                                          |                                               | No at 8 and 12 weeks |                                               |
| Rompe et al. [35], 2008 | ESWT                  | 25 (9)                           | 40.4 (11.3)         | >6 months            | 3                        | 1 week                | Radial 0.12×2000           | Crossover was allowed after 16 weeks follow-up        | 16 weeks and 15 months                              | Yes at 16 weeks | 15 months NR                             |
|                    | EE                     | 25 (11)                          | 39.2 (10.7)         |                      |                          |                      |                             |                                                          |                                               | No at 16 weeks | 1 year NR                                |

ESWT=Shock wave therapy, EE=Eccentric exercises, NR=Not reported

Among the five Achilles studies, two studies included patients with both insertional and non-insertional tendinopathy [21,22]. Among these studies, Peers [21] was the only study that reported a separate analysis of both groups (insertional and non-insertional). Rasmussen, Christensen [23] did not specify the type or location of the Achilles tendinopathy.
Table 2: Randomised control trials comparing shock wave to other interventions for patellar tendinopathy.

| Trial                  | ESWT | Placebo | >3 months | 1 week | Focused 0.5×2500 | None | 1,12 and 22 weeks | No |
|------------------------|------|---------|-----------|--------|-----------------|------|-----------------|----|
| Zwerver et al. [33]    | 31 (20) | 31 (21)  | 24.2 (5.2) | 3      | None            | 1.2 and 22 weeks | No |
| Vetrano et al. [37]    | 23 (20) | 23 (17)  | 26.8 (8.5) | 3      | Focused 0.17 to 0.25×2400 | Stretching, Strengthening exercises in both groups +Hydrotherapy | 2.6 and 12 months | No |

EE=Eccentric ex, NSAID=Non-steroidal anti-inflammatory drugs, PT=Physiotherapy, PRP=Platelet-rich plasma, NR=Not reported

Report of Adverse Events

Adverse events were reported in the Achilles studies: Two older patients (62 and 65 years) in the study by Costa et al. [22] ruptured their Achilles tendon. This could be considered as a serious adverse event. Some subjects receiving ESWT had reddening of the skin after low-energy SWT (n=25) [24]. No adverse events were reported in the Patellar studies.

Quality of Studies

Table 3 summarizes the methodological quality of the included studies using the PEDro scale. Effective subject blinding was achieved in all studies apart from one [22] whereas, assessor blinding was achieved in all studies.

| Trial                  | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | Total Score |
|------------------------|---|---|---|---|---|---|---|---|---|----|----|-------------|
| **Achilles**           |   |   |   |   |   |   |   |   |   |    |    |             |
| Taunton et al. (2003)  | Yes | Yes | No | No | Yes | No | Yes | Yes | No | Yes | No | 5/10         |
| Peers (2003)-Achilles tendon | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes | No | Yes | Yes | 8/10        |
| Peers (2003)-Patellar tendon | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes | No | Yes | Yes | 8/10        |
| Costa et al. (2005)    | Yes | Yes | Yes | No | No | No | Yes | No | Yes | No | Yes | 6/10         |
| Wang et al. (2007)     | Yes | No | No | Yes | No | No | Yes | No | Yes | No | Yes | 5/10         |
| **Patellar**           |   |   |   |   |   |   |   |   |   |    |    |             |
| Rompe et al.(2007)     | Yes | Yes | Yes | Yes | No | No | Yes | Yes | Yes | Yes | Yes | 8/10        |
| Rasmussen et al. (2008)| Yes | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes | 9/10        |
| Rompe et al. (2008)    | Yes | Yes | Yes | Yes | No | No | Yes | Yes | Yes | Yes | Yes | 8/10        |
| Zwerver et al. (2011)  | Yes | Yes | Yes | Yes | No | No | Yes | Yes | Yes | Yes | Yes | 9/10        |
| Vetrano et al. (2013)  | Yes | Yes | No | Yes | No | No | Yes | Yes | Yes | Yes | Yes | 7/10        |
1. Eligibility criteria specified 2. Random allocation 3. Concealed allocation 4. Baseline prognostic heterogeneity 5. Subject blinding 6. Therapist blinding 7. Assessor blinding 8. Outcomes obtained for >85% of initially allocated subjects 9. Intention to treat analysis 10. Between groups statistical comparisons reported 11. Point measures and measures of variability provided (PEDro, 1999).

Table 3: Methodological Quality of Included Trials.

Synthesis of Results

We conducted exploratory meta-analyses in an attempt to pool results for VISA-A, load induced pain and tenderness outcomes for Achilles and VISA-P outcomes for Patellar studies (Figure 2-5) however in all cases heterogeneity was considered to be high (12 range 71% to 92%). An I² value of 75% and above is considered high and this in turn would affect the generalisability of the findings of meta-analysis [25]. Pooled estimates were non-significant with confidence intervals crossing the line of no effect. These results must be considered as exploratory and interpreted with caution.

Tendon diameter on ultrasound scan was assessed in two studies [24,26] with contradicting results. To detect a significant difference in tendon structure post-treatment, a study might have to have a longer follow-up. Studies in the past that reported similar reduction in tendon thickness had a mean follow-up of more than three years [16,17] whereas studies included in this review had a mean follow-up of one year.

The studies on the Achilles tendinopathy did not report any statistically significant difference between groups with regards to functional objective measures whereas all Patellar studies included in this review reported functional improvement.

Discussion

These findings suggest that ESWT was not able to demonstrate a statistically significant improvement in VISA or load induced pain by meta-analysis compared to other treatments like eccentric exercises. Following meta-analysis, there were no significant differences between the intervention and control group on the pooled VISA-A scores (p=0.59, 95% CI-15.02, 26.51) or load-induced pain (p=0.51, 95% CI-3.15, 1.56) at 16 weeks for Achilles tendinopathy and no significant differences between the pooled VISA-P scores for patellar tendinopathy at 12 weeks (p=0.27, CI-7.86, 27.87).

Strengths and limitations of this study

Overall, the number of trials in this field is small and studies feature relatively small sample sizes. However, the included studies demonstrated reasonable quality with the PEDro score ranging from five to nine out of ten.

Our review was performed systematically and searched for both published and unpublished studies in a range of databases to try to provide a broad review of the trials of ESWT on lower limb tendinopathies. We included outcomes considered to be clinically relevant to healthcare providers and patients.

Our review has some limitations: Excluding studies published in languages other than English could lead to language bias. Additionally, study selection at the title and abstract stage was performed by one researcher (potentially resulting in selection bias) although they were supported by others to discuss uncertain cases and to confirm inclusion at full text stage. However within our resources every effort was made to minimise any systematic bias in this review.

Clinical implications

Interest and literature around ESWT is growing steadily and its use is established in in treating calcific tendinitis of the shoulder [27] and plantar fasciitis [28].

The included studies were heterogeneous in nature and therefore the results from the meta-analysis should be interpreted with caution. It remains largely unclear what parameters are the most important in using ESWT. Some studies utilised focussed and others radial ESWT. Intensities, interval between treatments and the total number of sessions also varied across the studies. Studies typically followed up subjects in the short to medium term and long-term effects are unclear. A systematic review on calcific tendinitis of the shoulder also
questioned the long-term effectiveness of ESWT [29]. Optimising the dose, delivery and timing of ESWT requires further investigation.

Furthermore, studies included in this review showed better results when eccentric exercises where introduced as co-interventions [21,23]. This finding is consistent with an earlier systematic review in chronic Achilles tendinopathy by Al-Abbad and Simon [6]. Eccentric exercises might assist in maintaining the effects of ESWT in the long-term. However, this theory warrants further investigation.

None of the studies included in this review utilised anaesthesia for the application of ESWT. The use of anaesthesia has been seen to reduce the effectiveness of ESWT in previous studies [30-32].

Complications can occur with ESWT. These are reported as erythema and inflammation [24] and Achilles tendon rupture in older patients [22]. Longer term monitoring for safety in greater numbers of patients would provide further information on risks associated with the intervention.

Concurrent sports participation is another factor which may affect the effectiveness of ESWT. Subjects in the study by Zwerver et al. [33] continued to take part in sport during the treatment period and this could have neutralised the beneficial effects of ESWT. A similar non-effective treatment was seen when eccentric exercises were used to treat jumper’s knee during a competitive season [34]. So a period of rest or restricting the subjects to minimal activities might be key in the successful treatment of tendinopathies.

Similarly, none of the studies reported economic evaluations, which should be considered to allow cost effectiveness decisions on treatment recommendations [35-37].

Recommendations

Considering the cost and investment required for a shock wave therapy machine and the findings of the review, careful consideration should be given to the implementation of such interventions. Other interventions like eccentric exercises may provide the same benefits as of ESWT. Where ESWT is already in use, increased number of sessions or co-interventions such as eccentric exercises might be required to maintain its long-term effectiveness. It may also be important to reduce loading of the tendon during the treatment phase by restricting the patient to lighter activities. Careful consideration also should be given when applying ESWT in older patients with degenerative tendons as it might lead to ruptures.

Conclusion

We produced a review that expanded upon previous reviews and addressed some methodological limitations. Studies were heterogeneous but taken overall, the findings suggest that ESWT was not able to demonstrate an improvement in outcomes compared to other available treatments such as eccentric exercises. Well-designed trials with optimised dosage and treatment protocols, adequate power, longer term follow-up and economic analyses are required to establish ESWT’s long-term effectiveness and cost effectiveness.

Competing interests

None declared.

Funding

No funding was received for this study.

Acknowledgements

We gratefully acknowledge assistance from Isla Kuhn, University of Cambridge Medical Library in literature searching and Dr. Ian Wellwood, Cambridge Institute of Public Health, University of Cambridge UK for comments on the manuscript. I would also like to extend my gratitude to J Zwerver, I Scheek and Mr. V D Worp, University Medical Centre, Netherlands, for sharing their data with us.

References

1. Scott A, Ashe MC (2006) Common tendinopathies in the upper and lower extremities. Curr sports med rep 5: 233-241.
2. Khan KM, Cook JL, Kannus P, Maffulli N, Bonar SF (2002) Time to abandon the ‘tendinitis’ myth. BMJ 324: 626-627.
3. Shrivastava SK, Kailash (2003) Shock wave treatment in medicine. J Biosci 30: 269-275.
4. Wilson M, Stacy J (2010) Shock wave therapy for Achilles tendinopathy. Curr Rev Musculoskelet Med 4: 6-10.
5. Wang CJ (2012) Extracorporeal shockwave therapy in musculoskeletal disorders. J Orthop Surg Res 7: 11.
6. Al-Abbad H, Simon JV (2013) The effectiveness of extracorporeal shock wave therapy on chronic achilles tendinopathy: a systematic review. Foot Ankle Int 34: 33–41.
7. Group DF, Berlin JA, Morton SC, Olkin I, Willianson GD, et al. (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (moose) group. Jama 283: 2008-2012.
8. Plint AC, Moher D, Morrison A, Schulz K, Altman DG, et al. (2006) Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review. Med J Aust 185: 263-267.
9. Santos CMD, Pimenta CAM, Nobre MR (2007) The PICO strategy for the research question construction and evidence search. Latin Ame J Nurs 15: 508-511.
10. Van-der-Worp H, Akker-Scheek ID, Van-Schie H, Zwerver J (2013) ESWT for tendinopathy: technology and clinical implications. Knee Surg Sports Traumatol Arthrosc 21: 1451-1458.
11. Visentini PJ, Khan KM, Cook JL, Kiss ZS, Harcourt PR, et al. (1998) The VISA score: an index of severity of symptoms in patients with jumper’s knee (patellar tendinosis). Victorian Institute of Sport Tendon Study Group, J Sci Med Sport 1: 22-28.
12. Robinson JM, Cook JL, Purdam C, Visentini PJ, Ross J, et al. (2001) The VISA-A questionnaire: a valid and reliable index of the clinical severity of Achilles tendinopathy. Brit J Sports Med. 35: 335-341.
13. Miller MD, Ferris DG (1993) Measurement of subjective phenomena in primary care research: the Visual Analogue Scale. Fam Pract Res J 13: 15-24.
14. Hjermstad MJ, Fayers PM, Haugen DF, Caraceni A, Hanks GW, et al. (2011) Studies comparing Numerical Rating Scales, Verbal Rating Scales, and Visual Analogue Scales for assessment of pain intensity in adults: a systematic literature review. J Pain Symptom Manage 41: 1073-1093.
15. Cook JL, Purdam CR (2009) Is tendon pathology a continuum? A pathology model to explain the clinical presentation of load-induced tendinopathy. Br J Sports Med 43: 409-416.
16. Obberg L, Lorentzon R, Alfredson H (2004) Eccentric training in patients with chronic Achilles tendinosis normalised tendon structure and decreased thickness at follow up. Br J Sports Med 38: 8-11.
17. Sunde K, Willberg L, Niklasson U, Werner S (2013) Does the tendinopathic patellar tendon normalise, according to ultrasound findings, after treatment with sclerosing injections or arthroscopic shaving? a long term follow-up (3-5 years). Br J sports Med 47: e2.
18. Maher CG, Sherrington C, Herbert RD, Moseley AM, Elkins M (2003) Reliability of the PEDro scale for rating quality of randomized controlled trials. Phys Ther 83: 713-721.
19. De-Morton NA (2009) The PEDro scale is a valid measure of the methodological quality of clinical trials: a demographic study. Aust J Physiother 55: 129-133.
20. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 151: 264-269.
21. Peers K (2003) Extracorporeal Shock Wave Therapy in Chronic Achilles & Patellar Tendinopathy. BCMJ 45.
22. Costa ML, Shepstone L, Donell ST, Thomas TL (2005) Shock wave therapy for chronic Achilles tendon pain: a randomized placebo-controlled trial. Clin Orthop Relat Res 440: 199-204.
23. Rasmussen S, Christensen M, Mathiesen I, Simonson O (2008) Shockwave therapy for chronic Achilles tendinopathy: a double-blind, randomized clinical trial of efficacy. Acta orthop 79: 249-256.
24. Rompe JD, Nafe B, Furia JP, Maffulli N (2007) Eccentric loading, shockwave treatment, or a wait-and-see policy for tendinopathy of the main body of the Achilles: a randomized controlled trial. Am J Sports Med 35: 374-383.
25. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
26. Wang CJ, Ko JY, Chan YS, Weng LH, Hsu SL (2007) Extracorporeal shockwave for chronic patellar tendinopathy. Am J Sports Med 35: 972-978.
27. Harniman E, Carette S, Kennedy C, Beaton D (2004) Extracorporeal shock wave therapy for calcific and noncalcific tendonitis of the rotator cuff: a systematic review. J Hand Ther. 17:132-151.
28. Thomson CE, Crawford F, Murray GD (2005) The effectiveness of extracorporeal shock wave therapy for plantar heel pain: a systematic review and meta-analysis. BMC Musculoskelet Disord 6:19.
29. Lee SY, Cheng B, Grimmer-Somers K (2011) The midterm effectiveness of extracorporeal shockwave therapy in the management of chronic calcific shoulder tendinitis. J Shoulder Elbow Surg 20: 845-854.
30. Labek G, Auersperg V, Ziernhold M, Poulos N, Bohler N (2005) Influence of local anesthesia and energy level on the clinical outcome of extracorporeal shock wave-treatment of chronic plantar fasciitis. Z Orthop Ihre Grenzgeb 143: 240-246.
31. Rompe JD, Meurer A, Nafe B, Hofmann A, Gerdesmeyer L (2005) Repetitive low-energy shock wave application without local anesthesia is more efficient than repetitive low-energy shock wave application with local anesthesia in the treatment of chronic plantar fasciitis. J Orthop Res 23: 931-941.
32. Pettrone FA, McCall BR (2005) Extracorporeal shock wave therapy without local anesthesia for chronic lateral epicondylitis. J Bone Joint Surg Am 87: 1297-1304.
33. Zwerer J, Hartgens F, Verhagen E, Van-der-Worp H, Scheek IDA, et al. (2011) No effect of extracorporeal shockwave therapy on patellar tendinopathy in jumping athletes during the competitive season: a randomized clinical trial. Am J Sports Med 39: 1191-1199.
34. Visnes H, Hoksrud A, Cook J, Bahr R (2005) No effect of eccentric training on jumper's knee in volleyball players during the competitive season: a randomized clinical trial. Clin J Sport Med 15: 227-234.
35. Rompe JD, Furia J, Maffulli N (2008) Eccentric loading compared with shock wave treatment for chronic insertional achilles tendinopathy. A randomized, controlled trial. J Bone Joint Surg Am 90: 52-61.
36. Taunton J, Taunton K, Khan K (2003) Treatment of patellar tendinopathy with extracorporeal shock wave therapy. Br Columbia Med J 45.
37. Vettrano M, Castorina A, Vulpiani MC, Baldini R, Pavan A, et al. (2013) Platelet-rich plasma versus focused shock waves in the treatment of jumper’s knee in athletes. Am J Sports Med 41: 795-803.